EDVA · Endovia Health Sciences, Inc.
$0.14
+0.01 (+5.78%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern for the next 12 months.”View the 10-Q filed Aug 19, 2026
Market Cap
$865,690
Shares
6.41M
Volume · Oct 20
49.07K
Avg daily vol (3M)
4.75M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.14
Open$0.15
Day$0.13–0.15
52W close$0.14–9.80
Avg vol 30d4.9M
Short int174K · 2.7% float · 1.0d
Short vol9%
Last earningsSep 30, 2024
DataJan 2020–Oct 2026
Filing10-Q · Aug 19
Up next
filed Aug 19, 2026
Date not confirmed
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$32,090
Trailing 12 months
Net income (TTM)
−$17.28M
Trailing 12 months
Revenue growth YoY
-93.8%
Year over year
Operating margin
-19,415.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$380,338
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+545.3%
Year over year · more shares
Price change (1Y)
-98.1%
Trailing year
Short interest
2.7%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−89%
below
Price vs 50-day avg
−48%
below
RSI (14)
26
oversold
MACD trend
Positive
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−44%
trailing
6-month return
−90%
trailing
YTD return
−95%
this year
Relative strength
−98%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
1 of 18 funds reported for Sep 30 · net -73.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.71% of float · ▼ -48.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Squeeze score
40
low risk · 0–100
Fundamentals
Revenue growth
−91%
Y/Y
Gross margin
23%
expanding
EPS growth
+32%
Y/Y
Balance sheet
$37.4K
net cash
Quant / Vol
risk profile
Volatility
187%
annualized · 1-yr
Max drawdown
−99%
past year
ATR
17.6%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−89%
Bearish
Price vs 50-day avg
−48%
Bearish
RSI (14)
26
Neutral
MACD trend
Positive
Bullish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
1 of 18 funds reported for Sep 30 · net -73.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
2.71% of float · ▼ -48.7% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
18 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $10
vs 200-day avg -89%
vs 50-day avg -48%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EDVA
this stock
Endovia Health Sciences, Inc.
|
$865,690 | -95.1% | -90.9% | — | 2.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +10.7% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +669.4% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +1.3% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$64.50B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EDVA | -7.5% | -44.0% | -90.5% | -23.2% | -95.1% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | -6.0% | -43.1% | -98.2% | -23.7% | -107.5% |